AC Immune (NASDAQ:ACIU) Shares Cross Below Fifty Day Moving Average – Time to Sell?

AC Immune (NASDAQ:ACIU) crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $2.95 and traded as low as $2.72. AC Immune shares last traded at $2.84, with a volume of 251,197 shares.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ACIU shares. Jefferies Financial Group restated a “buy” rating and set a $7.00 target price on shares of AC Immune in a research report on Friday, March 13th. Weiss Ratings downgraded AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 8th. BTIG Research reaffirmed a “buy” rating and issued a $8.00 price objective on shares of AC Immune in a research report on Monday, May 4th. Finally, Wall Street Zen raised AC Immune from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, AC Immune has a consensus rating of “Hold” and a consensus target price of $7.50.

AC Immune Stock Performance

The company has a market cap of $283.94 million, a PE ratio of -3.40 and a beta of 1.65. The company has a quick ratio of 1.02, a current ratio of 0.87 and a debt-to-equity ratio of 0.11. The stock’s 50 day simple moving average is $2.95 and its two-hundred day simple moving average is $3.09.

AC Immune (NASDAQ:ACIU) last issued its earnings results on Thursday, April 30th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.01. AC Immune had a negative return on equity of 125.26% and a negative net margin of 1,788.02%.The firm had revenue of $1.40 million for the quarter, compared to analysts’ expectations of $0.33 million. As a group, research analysts anticipate that AC Immune will post -0.68 earnings per share for the current year.

Institutional Trading of AC Immune

A number of institutional investors have recently modified their holdings of ACIU. Acadian Asset Management LLC grew its holdings in shares of AC Immune by 87.1% during the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock worth $679,000 after purchasing an additional 172,796 shares during the period. Sei Investments Co. acquired a new stake in shares of AC Immune in the second quarter worth $51,000. Private Advisor Group LLC acquired a new stake in shares of AC Immune in the third quarter worth $48,000. Susquehanna International Group LLP acquired a new stake in shares of AC Immune in the third quarter worth $63,000. Finally, Goldman Sachs Group Inc. boosted its stake in shares of AC Immune by 46.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after purchasing an additional 5,920 shares during the period. Hedge funds and other institutional investors own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.